# KalVista Pharmaceuticals (stock symbol: KALV) Logo in transparent PNG and SVG formats

## KalVista Pharmaceuticals Logo large

### KalVista Pharmaceuticals Logo large Download PNG (82.75 KB)

![KalVista Pharmaceuticals Logo large Download PNG (82.75 KB)](/img/orig/KALV_BIG-d6343165.png)

### KalVista Pharmaceuticals Logo large Download SVG (9.69 KB)

![KalVista Pharmaceuticals Logo large Download SVG (9.69 KB)](/img/orig/KALV_BIG-5ef70914.svg)

## KalVista Pharmaceuticals Logo icon format

### KalVista Pharmaceuticals Logo icon format Download PNG (41.46 KB)

![KalVista Pharmaceuticals Logo icon format Download PNG (41.46 KB)](/img/orig/KALV-205848a3.png)

### KalVista Pharmaceuticals Logo icon format Download SVG (1.4 KB)

![KalVista Pharmaceuticals Logo icon format Download SVG (1.4 KB)](/img/orig/KALV-ca0237b9.svg)

## KalVista Pharmaceuticals Logo large for dark backgrounds

### KalVista Pharmaceuticals Logo large for dark backgrounds Download PNG (83.21 KB)

![KalVista Pharmaceuticals Logo large for dark backgrounds Download PNG (83.21 KB)](/img/orig/KALV_BIG.D-14b1d195.png)

### KalVista Pharmaceuticals Logo large for dark backgrounds Download SVG (9.69 KB)

![KalVista Pharmaceuticals Logo large for dark backgrounds Download SVG (9.69 KB)](/img/orig/KALV_BIG.D-1d1d54c6.svg)

## KalVista Pharmaceuticals Logo icon format for dark backgrounds

### KalVista Pharmaceuticals Logo icon format for dark backgrounds Download PNG (41.84 KB)

![KalVista Pharmaceuticals Logo icon format for dark backgrounds Download PNG (41.84 KB)](/img/orig/KALV.D-48f5513d.png)

### KalVista Pharmaceuticals Logo icon format for dark backgrounds Download SVG (1.4 KB)

![KalVista Pharmaceuticals Logo icon format for dark backgrounds Download SVG (1.4 KB)](/img/orig/KALV.D-4124b8d1.svg)

## About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

1. Website domain: kalvista.com
2. Employees: 105
3. Marketcap: $0.29 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
